Tudor Investment Corp’s Intra-Cellular Therapies Inc. ITCI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-621,815
| Closed | -$82M | – | 3884 |
|
|
2025
Q1 | $82M | Buy |
+621,815
| New | +$77.5M | 0.27% | 33 |
|
|
2024
Q4 | – | Sell |
-31,478
| Closed | -$2.3M | – | 3608 |
|
|
2024
Q3 | $2.3M | Sell |
31,478
-20,423
| -39% | -$1.53M | 0.01% | 1120 |
|
|
2024
Q2 | $3.55M | Buy |
+51,901
| New | +$3.6M | 0.02% | 801 |
|
|
2024
Q1 | – | Sell |
-51,555
| Closed | -$3.69M | – | 2881 |
|
|
2023
Q4 | $3.69M | Buy |
51,555
+15,276
| +42% | +$879K | 0.03% | 782 |
|
|
2023
Q3 | $1.89M | Sell |
36,279
-5,697
| -14% | -$332K | 0.02% | 958 |
|
|
2023
Q2 | $2.66M | Buy |
+41,976
| New | +$2.62M | 0.03% | 736 |
|
|
2022
Q4 | – | Sell |
-50,158
| Closed | -$2.33M | – | 2934 |
|
|
2022
Q3 | $2.33M | Buy |
50,158
+31,431
| +168% | +$1.64M | 0.05% | 478 |
|
|
2022
Q2 | $1.07M | Buy |
+18,727
| New | +$1.06M | 0.03% | 844 |
|
|
2021
Q4 | – | Sell |
-18,678
| Closed | -$696K | – | 3126 |
|
|
2021
Q3 | $696K | Buy |
+18,678
| New | +$649K | 0.01% | 1427 |
|
|
2018
Q1 | – | Sell |
-31,965
| Closed | -$463K | – | 1295 |
|
|
2017
Q4 | $463K | Sell |
31,965
-28,026
| -47% | -$433K | 0.01% | 641 |
|
|
2017
Q3 | $947K | Buy |
+59,991
| New | +$880K | 0.02% | 411 |
|
|
2015
Q4 | – | Sell |
-60,637
| Closed | -$2.43M | – | 1881 |
|
|
2015
Q3 | $2.43M | Buy |
+60,637
| New | +$1.98M | 0.08% | 162 |
|
|
2014
Q2 | – | Sell |
-20,000
| Closed | -$364K | – | 1357 |
|
|
2014
Q1 | $364K | Buy |
+20,000
| New | +$361K | 0.02% | 690 |
|
Other funds holding ITCI
KIM
HNB
Tudor Investment Corp's ITCI Position: Q2 2025 in Review
Tudor Investment Corp sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 621,815 shares — an estimated $82M sold.
Tudor Investment Corp first reported a position in ITCI in Q1 2014 and held it in 13 quarters. The position peaked at $82M in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.
- Tudor Investment Corp reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
- Tudor Investment Corp sold 621,815 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $82M.
- Tudor Investment Corp first reported a position in Intra-Cellular Therapies Inc. in Q1 2014 and held it in 13 quarters.
- Tudor Investment Corp's Intra-Cellular Therapies Inc. position peaked at $82M in Q1 2025.
- 4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.
Based on Tudor Investment Corp's 13F filing for Q2 2025, filed 14 Aug 2025.